Gen: Top 10 winners of Wall Street biomedical stocks in 2014

Source: Biovalley, January 21, 2015, 2014 was an extraordinary year for the capital market and a year for biomedical stocks to climb the summit In this year, biotechnology has risen to an unprecedented level and become the most valuable investment area in all industries Biomedical stocks generally performed very well in this year and significantly outperformed the market Recently, the famous foreign website Gen released the top 10 winners list of Wall Street biomedical stocks in 2014 According to the data, the growth rate of ranking in top 10 in 2014 is generally higher than that in 2013 For example, insys therapeutics, the biggest gainer in 2013, rose 439%, while avanir pharmaceuticals, the biggest winner in 2014, rose 487% However, the bottom ten winners in 2014 saw a slightly lower stock gain than the top ten winners in 2013 (277.1% vs 291.1%), but the performance of the stock is still eye-catching, almost double Here are the top 10 biomedical stocks on Wall Street in 2014 (closing price from December 19, 2013 to December 19, 2014) Most of them are emerging companies with small to medium market value The good news that stimulates the stock price surge of these companies includes regulatory approval, exciting clinical data and rumors of being acquired by large companies It should be noted that the two companies ranked first and tenth on the 2014 list are likely to disappear from the 2015 Wall Street list because they are being acquired by larger pharmaceutical companies In addition, the companies listed in 2014 are not included in the list due to less than one year of stock price data Here's a detailed description of each company: No 1: avanir pharmaceuticals: 487.1% up: Alzheimer's disease (AD) has always been a disaster area for new drug research and development, with a clinical failure rate of 99.6%, so any positive data is exciting Avanir is a California based biopharmaceutical company that specializes in the research and development of drugs for the treatment of central nervous system diseases Its products on the market include nuedexta, which is the first and only FDA approved drug for the treatment of pseudobulbar emotion (PBA) In addition, avanir is also developing another compound drug avp-923 for the treatment of Alzheimer's disease (AD) According to the data released by avanir on September 15, 2014, avp-923 has been proved to be able to significantly calm the anxiety of patients with Alzheimer's disease (AD) in a phase II clinical trial The data has been published, and the stock price of avanir has soared 85% On December 3, 2014, Otsuka, a Japanese pharmaceutical company, announced a US $3.5 billion acquisition of avanir, which led to the stock price of avanir rising nearly 13% (to US $16.92), in a move intended to create a global giant in the field of central nervous system The transaction is expected to be completed in the first quarter of 2015 (related reading: Japan's Otsuka acquired avanir for us $3.5 billion, creating a global giant of central nervous system) second place: Agios pharmaceuticals increased by 449.0% Note: on April 6, 2014, Agios released preliminary positive clinical data of experimental leukemia drug ag-221 phase I, 3 of 7 patients experienced complete remission, and another 2 patients experienced complete remission Cases experienced complete remission but the platelets did not recover completely Data has been released, and Agios shares are up 28% Ag-221 is a novel mutant inhibitor of isocitrate dehydrogenase 2 (idh2), which was developed by Agios in cooperation with celgene, a biotechnology giant On September 26, 2014, Agios announced that it would release preliminary clinical data of another experimental drug ag-120 phase I in November, which is an oral IDH1 inhibitor Inspired by this news, Agios shares rose 19% to $63.76 On November 18, 2014, Agios released the positive data of ag-120 Four of the seven patients had complete remission On November 19, Agios shares soared 14.5% to 95.97% No 3: ova science increased by 438.2%, indicating that the stock price of ova science remained stable in the first half of 2014, but after the release of the second quarter data and the progress of the international deployment of infertility treatment drugs, the stock price of ova science soared all the way since August On December 17, ovascience announced that it would promote all three fertility treatment programs (augmentsm, ovaprimesm, ovaturesm), with the share price rising 19% to $34.96; a day later, wedbush securities raised the stock rating of ovascience from neutral to outperform, and predicted the stock price target price of $47, which led to the stock price of ovascience rising 24% to 43.22 US dollars No 4: receptos rose 426.9%, indicating that in the first five months of 2014, the stock price of receptos went up and down, but began to rise in June On October 28, receptos released the phase II clinical positive data of rpc1063, a candidate drug for ulcerative colitis, which triggered the stock price to rise 41% to $95.76 The primary end point and all secondary end points were achieved After that, Credit Suisse raised the target price of receptos from $75 to $125, while maintaining its "outperform the market" rating No 5: TG therapeutics up: 358.2% indicates that TG Company released a series of clinical positive data in 2014, driving the share price of the company soaring all the way On June 11-13 this year, TG announced that the combination therapy of experimental drug tg-1101 (ublituximab) and pharmacyclics / Janssen drug ibrutinib achieved a total remission rate of 90% in phase II clinical treatment, 6 of 7 cases of chronic lymphoblastic leukemia (CLL) and all 3 cases of MCL achieved remission After the data was released, the company's share price rose 32% to US $9.61 On September 15, TG announced an earlier than expected agreement with the phase III clinical protocol in tg-1101, and its share price rose another 16% On December 9, TG released the data of phase I / II treatment of B-cell malignant tumor with tg-1101 and tgr-1202, a candidate drug of another company, which triggered the stock price of TG to soar 30.5% to $18.25 in three days No 6: Achillion pharmaceuticals: 354.0% increase: in the first five months of 2014, Achillion's share price has been ups and downs But on June 10, the company announced two good news, which stimulated the share price to soar 83%; one of them was the experimental hepatitis C drug ach-3422 phase I clinical application, and the FDA lifted the clinical restrictions on the drug sovaprevir, allowing it to be used in clinical trials for the treatment of hepatitis C patients On November 10, Achillion announced the first trading day of ach-3102 / sovaprevir combination therapy after phase I clinical exciting data of genotype 1 hepatitis C, the share price rose 27% again The phase I clinical data of the combination therapy showed that all 12 patients achieved sustained virological response (svr12) 12 weeks after treatment 7th place: Bluebird bio increase: 348.6% indicates that since June 2014, the share price of Bluebird has soared twice On June 16, the first trading day after Bluebird released positive data on hgb-205 clinical research of lentivirus gene therapy candidate product lentigobin bb305 for β - thalassemia, its share price soared 32% On December 9, the next trading day after Bluebird announced that the first four patients who received bb305 treatment after hgb-205 clinical study follow-up for at least three months had enough hemoglobin to reduce or eliminate transfusion support, the company's share price soared 83% to $84.28 No 8: pernix therapeutics increased by 292.3%, indicating that pernix company released several good news in 2014 to stimulate its share price On February 5, Doug Drysdale was appointed CEO and disclosed a $65 million institutional investment for future acquisition of specialty products, which stimulated investors to bid up the share price by 69% to $3.53 On March 17, pernix reported a 38% increase in revenue for the fiscal year 2013, spurring its share price to climb 58% to $5.93 Two months later, on May 15, pernix announced a $250 million acquisition of the migraine drug treximet from GSK, prompting shares to rise another 15% to $6.43 On November 10, pernix released its third quarter data showing that the listing of treximet led to a 72% increase in net income in the third quarter over the same period in 2013, driving the share price up 14.5% to $11.35 9th place: Amicus therapeutics: 278.8% increase: Amicus is developing the experimental drug migalastat for Fabry's disease On August 7 this year, the company released strong data for the second quarter, as well as very exciting and positive data for migalastat III clinical, which stimulated the share price of the company to soar 81% to $7.27 in the next 21 days In September and October, after Amicus released more positive data on migalastat's cardiovascular and composite secondary endpoints, the company's share price rose 18% in the first trading day of November 17 In the 12 days from November 14 to 26, the share price rose another 43% to $8.13 10th place: prosensa holding gain: 277.1% indicates that prosensa's candidate drug for DMD, drisapersen, failed in a phase III clinical trial in 2013, leading to the end of cooperation with GSK, and the stock price plummeted 70% in a single day Although not immediately recovered, prosensa's share price began to recover on May 27, rising 39% to $11.03 in three days Translana, another DMD drug developed by PTC therapeutics, has been approved by the European Union, which makes investors have a good prospect for DMD drugs On November 24, 2014, bio Marin, a famous rare disease drug R & D company, announced the acquisition of prosensa for us $840 million, which made its share price soar 63% to US $18.6.